A summer blockbuster

BY JON GARINN
PUBLISHED: AUGUST 11, 2011
We rarely report on Phase 1 trials, primarily because they involve a small number of patients and are limited in scope to studying side effects and establishing a safe administration of treatment. But there's good reason for us to make an exception. The news this week that scientists at the University of Pennsylvania had, for the first time, used gene therapy to treat a form of leukemia is not only welcome but long awaited.

You see, it's been more than two decades since researchers hailed gene therapy as the next big thing in medicine. The theory is fairly straightforward: If a damaged gene causes a disease, simply introduce a healthy version of the gene and the disease will be cured.

The problem was getting those healthy genes into the cells that needed them. The solution: viruses, which are preprogrammed to deliver their own DNA into the cells they infect. By re-engineering viruses to deliver helpful rather than harmful genes, scientists could theoretically make an effective therapy.

But cancer isn't like most other diseases. Because it arises in the body's own cells, the immune system isn't prone to attacking it. So in this study of three patients with advanced chronic lymphocytic leukemia (CLL), the researchers removed the patients' T- cells and reprogrammed them to recognize and attack B cells, the malignant blood component of CLL. Then, by enlisting the help of a deactivated form of HIV, the researchers injected these modified T-cells back into to the patients and unleashed an army of cancer killers.

Most important, these "reinvigorated" T-cells managed to reawaken T-cells that had been suppressed by the leukemia, and even helped generate "memory" T-cells that remained for a long time, ensuring that this invading force would not only wipe out the leukemia but also guard against its return.

Sounds like a set-up for the summer's biggest action-adventure blockbuster, doesn't it?

Check the studies published in The New England Journal of Medicine and Science Translational Medicine.

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
BRCA Mutations May Cause Drug Resistance in Breast and Ovarian Cancer
There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.
Sarah Sciortino on Fertility and Sexuality in Younger Patients with Ovarian Cancer
Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.
Caring With Confidence: Study Examines Caregiver Mastery and Patient Survival in GBM
A recent study found that the level of family caregiver mastery may have an effect on the survival of patients with glioblastoma.
Related Videos
Examining Quality of Life Issues for Patients With MPNs
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
Elliott Winton on the Changing Landscape of MPN Treatment
Elliott Winton, M.D., researcher, physician and 2016 MPN Hero, discusses some of the drastic changes that happened over the past decade or so in the world of MPNs. 
Siddhartha Mukherjee on Increasing MPN Awareness
Siddhartha Mukherjee, M.D., Ph.D, an oncologist, researcher and Pulitzer Prize-winning science writer, discusses the increasing awareness about myeloproliferative neoplasms (MPNs).
x
//For side ad protocol